InTrack Investment Management Inc Reduces Stock Position in Zoetis Inc. $ZTS

InTrack Investment Management Inc lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 10.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,369 shares of the company’s stock after selling 501 shares during the quarter. InTrack Investment Management Inc’s holdings in Zoetis were worth $681,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Maryland State Retirement & Pension System increased its holdings in Zoetis by 2.6% in the second quarter. Maryland State Retirement & Pension System now owns 21,690 shares of the company’s stock valued at $3,383,000 after buying an additional 542 shares during the last quarter. First Merchants Corp increased its holdings in Zoetis by 2.9% in the second quarter. First Merchants Corp now owns 26,547 shares of the company’s stock valued at $4,140,000 after buying an additional 745 shares during the last quarter. Narwhal Capital Management purchased a new position in Zoetis in the second quarter valued at $657,000. Citizens National Bank Trust Department increased its holdings in Zoetis by 19.8% in the second quarter. Citizens National Bank Trust Department now owns 8,119 shares of the company’s stock valued at $1,266,000 after buying an additional 1,341 shares during the last quarter. Finally, REAP Financial Group LLC increased its holdings in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Argus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Wednesday. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Moderate Buy” and a consensus price target of $200.88.

Zoetis Trading Up 0.6%

Shares of ZTS opened at $143.61 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a 50 day simple moving average of $149.41 and a 200-day simple moving average of $154.74. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55. The stock has a market cap of $63.65 billion, a price-to-earnings ratio of 24.72, a price-to-earnings-growth ratio of 2.29 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same period last year, the company posted $1.56 EPS. The company’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.